The Technical AnalystExchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Bachem Holding AG Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.29% CHF80.15
America/New_York / 30 apr 2024 @ 11:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6 009.14 mill |
| EPS: | 1.500 |
| P/E: | 53.43 |
| Earnings Date: | Jul 24, 2024 |
| SharesOutstanding: | 74.97 mill |
| Avg Daily Volume: | 0.0883 mill |
| RATING 2024-04-30 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 2.11x |
| Company: PE 53.43 | sector: PE 25.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 3.13x |
| Company: PE 53.43 | industry: PE 17.08 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CHF5.28 (-93.42%) CHF-74.87 |
| Date: 2024-05-01 |
| Expected Trading Range (DAY) |
|---|
|
CHF 77.98 - 82.32 ( +/- 2.71%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CHF80.15 (-1.29% ) |
| Volume | 0.0678 mill |
| Avg. Vol. | 0.0883 mill |
| % of Avg. Vol | 76.77 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BANB.SW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BANB.SW
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.